Primary End Point Data From the RADIANCE-HTN SOLO Trial

Evaluation of the Paradise System in hypertension.


The RADIANCE-HTN SOLO trial is evaluating the ParadiseĀ® Renal Denervation System for lowering blood pressure. The animation summarizes the RADIANCE-HTN SOLO study design and primary endpoint results. The ParadiseĀ® System is approved for sale in markets regulated by the CE mark. Investigational device in the U.S., limited by U.S. Federal law to investigational use only in the United States.